Table 2.
Baseline characteristics of the 209 adolescents living with perinatally-acquired HIV included in the COHADO cohort according to sites, Abidjan (Côte d'Ivoire), Lomé (Togo) IeDEA-pWADA, 2015–2017.
| Total | Abidjan, Côte d'Ivoire | Lomé, Togo | P-Valuea | |
|---|---|---|---|---|
| N = 209 (%) | N = 108 (%) | N = 101 (%) | ||
| Sex n (%) | 0.25 | |||
| Males | 95 (45.4) | 45 (41.7) | 50 (49.5) | |
| Females | 114 (54.6) | 63 (58.3) | 51 (50.5) | |
| HIV disclosure performed, n (%) | <0.01 | |||
| Yes | 87 (41.6) | 61 (57.4) | 25 (24.8) | |
| No | 122 (58.4) | 45 (42.6) | 76 (75.2) | |
| Education level, n (%) | 0.01 | |||
| Primary school | 80 (38.3) | 31 (28.7) | 49 (48.5) | |
| Middle schools | 103 (49.3) | 61 (56.5) | 42 (41.6) | |
| High schools | 26 (12.4) | 16 (14.8) | 10 (9.9) | |
| Residential environment, n (%) | 0.91 | |||
| Urban | 187 (89.9) | 96 (88.9) | 91 (90.1) | |
| Rural | 22 (10.1) | 12 (11.1) | 10 (9.9) | |
| Electricity access, n (%) | 0.43b | |||
| Yes | 203 (97.1) | 106 (98.1) | 97 (96.0) | |
| No | 6 (2.9) | 2 (1.9) | 4 (4.0) | |
| Running water access, n (%) | <0.01 | |||
| Yes | 131 (62.7) | 101 (93.5) | 30 (29.7) | |
| No | 78 (37.3) | 7 (6.5) | 71 (70.3) | |
| Living with, n (%) | 0.65 | |||
| Both parents | 50 (23.9) | 27 (25.0) | 23 (22.8) | |
| Only one parent | 93 (44.5) | 50 (46.3) | 43 (42.6) | |
| Other family member | 66 (31.6) | 31 (28.7) | 35 (34.6) | |
| Orphanhood, n (%) | 0.03 | |||
| No | 91 (43.5) | 44 (40.7) | 47 (46.5) | |
| One parent | 91 (43.5) | 55 (50.9) | 36 (35.6) | |
| Two parents | 27 (13.0) | 9 (8.4) | 18 (17.8) | |
| WHO clinical stage, n (%) | <0.01 | |||
| 1, 2, 3 | 173 (83.8) | 105 (97.2) | 68 (67.3) | |
| 4 (AIDS) | 36 (17.2) | 3 (2.8) | 33 (32.7) | |
| ART regimen, n (%) | 0.48 | |||
| 2 NRTI+1NNRTI | 168 (81.2) | 88 (83.0) | 80 (79.2) | |
| 2 NRTI+1PI | 39 (18.8) | 18 (17.0) | 21 (20.8) | |
| Good ART adherence†, n (%) | <0.01b | |||
| Yes | 118 (56.4) | 57 (52.7) | 61 (51.6) | |
| No | 57 (27.3) | 24 (22.2) | 33 (32.6) | |
| Missing | 34 (16.3) | 27 (25.0) | 7 (6.9) | |
| Virological suppression, n/N (%) | ||||
| (viral load <50 cp/mL) | <0.01 | |||
| Yes | 2/62 (3.2) | 0/53 (0.0) | 2/9 (22.2) | |
| No | 60/62 (96.8) | 53/53 (100.0) | 7/9 (77.8) | |
| CD4 cell count/mm3, median [IQR] | ||||
| 521[281–757] | 540[314–753] | 484[271.5–760] | 0.71c | |
| Age at inclusion in years, median [IQR] | ||||
| 13[11–15] | 14[12–15] | 12[11–15] | 0.01c | |
| ART duration in years, median [IQR] | ||||
| 6[4–10] | 9[7–11] | 5[2–6] | <0.01c | |
| Age at ART initiation, median [IQR] | ||||
| 7[4–10] | 5[3–8] | 9[6–11] | <0.01c |
a
Chi2 test;
b
Fisher's exact test;
c
Wilcoxon-Mann-Whitney test.
†
More than 95% of planned doses taken. ART, Antiretroviral therapy.